Targeting TGF-β with selective inhibitors or neutralizing antibodies has demonstrated the ability to reverse macrophage-induced immunosuppression, restore CD8+ T-cell activity, and synergize with checkpoint blockade in preclinical and early clinical studies of NSCLC. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.